Wockhardt Receives Warning Letter Over Sterility, Data Integrity Concerns

Drug GMP Report
A A
Wockhardt is in hot water with the FDA again, receiving another warning letter for significant GMP violations regarding quality and data controls.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00